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Treatment with a single low dose (80 to 800 ng) of interleukin-1 (IL-1 ) 24 h before a lethal bacterial challenge 
of granulocytopenic and normal mice enhances nonspecific resistance. Since IL-1 induces secretion of 
acute-phase proteins, liver proteins which possess several detoxifying effects, we investigated the role of these 
proteins in the IL-l-induced protection. Inhibition of liver protein synthesis with u-galactosamine (GALN) 
completely inhibited the IL-l-induced synthesis of acute-phase proteins. GALN pretreatment abolished the 
protective effect of IL-1 on survival completely (neutropenic mice infected with Pseudomonas aeruginosa) or 
partially (nonneutropenic mice infected with Klebsiella pneumoniae). Pretreatment with IL-6, a cytokine 
induced by IL-1, did not reproduce the protection offered after IL-1 pretreatment, nor did it enhance or 
deteriorate the IL-1-enhanced resistance to infection. A protective effect of IL-1 via effects on glucose 
homeostasis during the acute-phase response was investigated by comparing plasma glucose levels in 
IL-l-treated mice and control mice before and during infection. Although glucose levels in IL-l-pretreated mice 
were somewhat higher in the later stages of infection, no significant differences from levels in control mice were 
present, and the glucose levels in control-treated animals never fell to hypoglycemic values. We conclude that 
the IL-l-induced nonspecific resistance is mediated neither by the induction of IL-6 nor by the effects of IL-1 
on glucose homeostasis. Acute-phase proteins generated after IL-1 pretreatment, however, seem to play a 
critical role in the IL-l-induced protection to infection.
Administration of the proinflammatory cytokine interleu­
kin-1 (IL-1) has been shown to enhance nonspecific resis­
tance in animals to several gram-positive and gram-negative 
bacteria, fungi, and plasmodia (35). The exact mechanism of 
this protection is still unclear. A direct antimicrobial effect of 
IL-1 in vitro (30) has been excluded, and enhanced clearance 
of microorganisms induced by IL-1 in vivo has not been a 
constant finding (22, 30). The protective effect of IL-1 to 
infectious challenges in granulocytopenic mice indicates that 
an effect on neutrophils does not mediate the IL-l-induced 
resistance (30, 35). Additional studies have provided evi­
dence against a major role of IL-l-induced cyclo-oxygcnase 
metabolites, glucocorticosteroids, or cytokines like IL -8 or 
tumor necrosis factor (TNF) in the IL-l-induced protection
(30, 33-35).
In the present study, we investigated whether the effects 
of IL-1 on the acute-phase response could be responsible for 
the increased resistance induced by IL-1.
The acute-phase response comprises a constellation of 
metabolic, endocrinologie, neurologic, and immunologic al­
terations which starts within hours of an initiating stimulus. 
These changes appear to be meant to balance or curtail the 
potential adverse consequences of the inflammatory process 
and restore homeostasis (15). Synthesis of acute-phase pro­
teins by the liver is a major component of the acute-phase 
response, and IL-1 appears to be an important inducer. We 
addressed the issue of whether enhanced resistance to 
infection after preexposure to IL-1 might be due to IL-l- 
induced enhanced secretion of acute-phase proteins using 
D-galactosamine (GALN), a liver-specific blocker of RNA 
and protein synthesis which acts by depleting UTP and
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thereby is able to block protein synthesis in the acute phase 
of infection (5). We investigated the extent to which GALN 
inhibits the IL-l-induced acute-phase protein secretion by 
the liver. Next, we assessed whether GALN  would also 
inhibit the IL-l-induced enhanced survival of normal and 
neutropenic mice after a lethal gram-negative bacterial chal­
lenge. Since IL-1 has been shown to induce IL -6 production 
by endothelial cells, fibroblasts, macrophages, and other cell 
types, it has been proposed that IL -6 is the direct mediator of 
a number of activities that were originally attributed to IL-1 
(11, 32). IL -6 induces a series of acute-phase proteins and in 
addition possesses some other potentially protective effects 
during an infection (12, 32). Hence, we studied the role of 
IL -6 in IL-l-induced protection.
Another component of the acute-phase response to trauma 
and infection is carbohydrate dyshomeostasis. During se­
vere infection, especially in rodents, an initial hyperglycemia 
may devolve into a profound hypoglycemia, the latter being 
a sign of decompensation (7). Since IL-1 affects glucose 
metabolism in various ways (29), we addressed the question 
of whether the effects of IL-1 on glucose homeostasis 
resulted in enhanced survival.
(Part of this paper was presented at the Third International 
Workshop on Cytokines, Stresa, Italy, 10 to 14 November 
1991 [M. T. E. Vogels and J. W. M. van der Meer, Cytokine 
3:518, 1991, abstract].)
MATERIALS AND METHODS
Mice. Female outbred Swiss mice (weight, 20 to 25 g; 
TNO, Rijswijk, The Netherlands) were kept under specific- 
pathogen-free conditions with a light-dark cycle of 12 h 
(lights on at 7 a.m., lights off at 7 p.m.). Standard lab chow 
(RMH-TM; Hope Farms, Woerden, The Netherlands) and
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acidified water were available ad libitum. Granulocytopenic 
mice received irradiated food.
Materials. Recombinant human IL-lß (rhIL-lß) was 
kindly provided by P. Graber (Glaxo, Geneva, Switzerland) 
and P. Ghiara (Sciavo, Siena, Italy). According to the 
specifications of the suppliers, endotoxin contamination was 
negligible (<1.53 and <1.2 ng/mg, respectively). Recombi­
nant human IL -6 (rhIL-6) was generously supplied by P. 
Stutz, Sandoz Research Institute, Vienna, Austria. Endo­
toxin contamination was <0.4 U/mg in the Limulus assay. 
Recombinant murine IL -6 (rmIL-6) was a kind gift from J. L. 
Renauld, Ludwig Institute for Cancer Research, Brussels, 
Belgium. Cytokines were stored undiluted at —70°C 
(rhIL-lß and rhIL-6) or 4°C (rmIL-6) and were diluted 
immediately before use in pyrogen-free isotonic phosphate- 
buffered saline (PBS; pH 7.4). Inactivated IL-1 was prepared 
by heating IL-1 at 95°C for 30 min. To all these solutions, 
normal mouse serum was added to an end volume of 2% 
(vol/vol). GALN  was purchased from Merck, Darmstadt, 
Germany, and was dissolved in pyrogen-free saline shortly 
before injection. Endotoxin content was <38 pg of GALN 
per g. Gentamicin was purchased from Schering, Kenil­
worth, N .J. Cyclophosphamide (ASTA Pharma, Frankfurt, 
Germany) was dissolved in sterile pyrogen-free distilled 
water. Bacteria for infectious challenges (Klebsiella pneu­
moniae ATCC 43816 and Pseudomonas aemginosa ATCC 
27853) were cultured overnight and washed three times in 
saline, and appropriate dilutions were prepared.
Experimental procedures. All experiments started at 9:30
a.m. (time zero).
(i) Liver enzymes, acute-phase proteins, and IL-6 and 
glucose levels after treatment with IL-1 and/or GALN. For 
assessment of liver injury by GALN , aspartate aminotrans­
ferase (ASAT) and alanine aminotransferase (ALAT) levels 
were determined in sera obtained from mice 24 h after 
intraperitoneal (i.p.) injection of different doses of GALN , 
400 ng of rhIL-lß, or PBS. For determinations of acute- 
phase proteins and IL -6 levels, mice received two injections. 
GALN or vehicle (saline) was given i.p. at -30 min, and 
IL-1 or control treatment (heat-inactivated IL-1) was admin­
istered i.p. (0.1 ml) at time zero. At various time points, 
blood was taken rctro-orbitally from ether-anesthetized mice 
to prepare EDTA-treated plasma (fibrinogen measurements) 
or serum (serum amyloid A [SAA] and IL -6 measurements). 
IL -6 levels were also measured in serum obtained at different 
time points after a single i.p. treatment with 800 ng of 
rhIL-lß or 800 ng of rhIL-6.
In the experiments in which glucose was measured, mice 
received a single i.p. injection of 800 ng of IL-1 or vehicle at 
time zero, an intramuscular (i.m.) challenge with K. pneu­
moniae at 24 h, and gentamicin (120 mg/kg subcutaneously)
6 h later. Trunk blood of decapitated mice was collected at 
several time points in fluoride-coated tubes on melting ice. 
All plasma and serum samples were stored at -20°C until 
assay.
When neutropenic mice were used, neutropenia (<0.5 x 
10g granulocytes per liter) was induced by two subcutaneous 
injections of cyclophosphamide (150 and 100 mg/kg, respec­
tively) on days -3 and 0.
(ii) Effects of cytokine and/or GALN pretreatment on sur­
vival. For survival experiments, some mice were rendered 
neutropenic as described above. IL-1 or control treatment 
(heat-inactivated IL-1) was administered i.p. (0.1 ml) at time 
zero. GALN  (18 mg per mouse) or vehicle (saline) was given 
i.p. 30 min earlier. The infectious challenge was adminis­
tered at 24 h. Neutropenic mice received P. aeruginosa i.m.
(0.5 x 10s to 1 x 10s CFU per mouse). Because P. 
aemginosa does not kill nonneutropenic mice unless very 
high inocula are used, such mice received K. pneumoniae (1 
x 106 to 5 x 10h CFU per mouse). Six hours after the 
infectious challenge, 120 mg of gentamicin per kg of body 
weight was given subcutaneously in order to postpone the 
time of death and thus accentuate the differences between 
treatment groups. Mortality was recorded for a period of at 
least 48 h after challenge.
In investigations on the protective effect of human and 
murine IL -6 on P. aeruginosa infection in neutropenic mice, 
the experimental protocol described above was used. The 
cytokines were given i.p. (0.1 ml) at time zero, and when both 
IL-1 and IL -6 were administered, a mixture of both cytokines 
was prepared immediately before injection. In all cases, 
heat-inactivated IL-lß was given as the control treatment.
Assays. Scrum ASAT and ALAT levels were assessed by 
routine procedures (BM/Hitachi 747; Boehringer Mannheim, 
Mannheim, Germany). Plasma glucose concentrations were 
determined by the hcxokinase method (Cobas Bio; Hoff- 
mann-LaRoche B.V., Mijdrecht, The Netherlands). IL -6 
levels in serum were quantitated as hybridoma growth factor 
activity by using the IL-6-dependent murine hybridoma 
7TD1 (a kind gift from J. van Snick) as described previously 
(28). Hybridoma growth factor activity resulting in half- 
maximal stimulation of the target cell growth was arbitrarily 
defined as 1 U. The reference standard in these experiments 
was rhIL -6 (specific activity, 107 U/ml; a kind gift from 
Immunex Corp., Seattle, Wash.). The detection limit of the 
assay was 50 U/ml. SAA was measured by a modification of 
the direct-binding enzyme-linked immunosorbent assay 
method for human plasma (27) by using a mixture of rabbit 
polyclonal antisera to mouse SAA! and SAA 2 (kind gift from 
J. Sipe, Boston, Mass.). Assays for fibrinogen in EDTA- 
plasma were performed by measuring the rate of conversion 
of fibrinogen to fibrin in the presence of thrombin excess. 
Measurements of fibrin clot formation were performed on a 
coagulometer (KC-10; Salm & Kipp, Breukelen, The Neth­
erlands). The results are expressed as milligrams of fibrino­
gen per liter of plasma; the sensitivity of the assay was 1,200 
mg/liter. Endotoxin levels were assessed by the Limulus 
amebocyte lysate gelation test, which had a sensitivity of 6 
pg/ml.
Statistical analysis. Survival curves were analyzed by the 
log rank test (24). Comparisons of medians of liver enzymes, 
acute-phase proteins, IL -6 levels, and glucose levels be­
tween treatment groups were made by the Kruskal-Wallis 
test at each time point (13). When five components were 
analyzed, the Bonferroni-corrected a = 0.05/5 = 0.01 was 
used.
RESULTS
Hepatotoxicity of GALN. Since GALN  is potentially hep- 
atotoxic (5), we first assessed the effect in Swiss mice of 
different doses of this hexosamine on ASAT and ALAT 
levels in serum at 24 h after i.p. injection. At this time point, 
liver damage should have developed (5). After administra­
tion of 18 and 36 mg of GALN  per mouse (720 and 1,440 
mg/kg, respectively), doses which are commonly used by 
others (1, 18, 37) and which are reported to be effective in the 
inhibition of protein synthesis (1, 5), serum ASAT and 
ALAT levels in normal mice did not differ significantly from 
those in vehicle-treated mice; 90 and 180 mg of GALN  per 
mouse induced a significant increase in the levels of both 
enzymes compared with the levels in vehicle-treated mice
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FIG . 1. Median ASAT and ALAT concentrations in sera of 
normal mice 24 h after i.p. injection of PBS, 400 ng of IL-1, or 
different doses of G A LN  (six to eight mice per group). In compar­
ison with PBS-treated mice, enzyme levels were significantly ele­
vated after administration of 90 mg of G A LN  (ASAT, P = 0.007; 
ALAT, P = 0.0027) and 180 mg of G A LN  (P = 0.009 for both ASAT 
and ALAT). Bars indicate the results for mice treated as follows 
(from left to right, respectively): PBS, 400 ng of IL-1, 18 mg of 
G A LN , 36 mg of G A LN , 90 mg of G A LN , and 180 mg of G A LN .
(Fig. 1). In neutropenic mice, ASAT and ALAT levels in 
mice after administration of 18 mg of GALN did not differ 
significantly from those in vehicle-treated mice; ASAT levels 
were elevated significantly compared with those in vehicle- 
treated mice after administration of 180 mg of GALN (P < 
0.0005), and ALAT levels were significantly increased after 
administration of 36 and 180 mg of GALN  {P < 0.01 and P <
0.0001, respectively) (data not shown). Also, ASAT and 
ALAT levels in normal and neutropenic mice 24 h after 
treatment with two i.p. injections of 18 mg of GALN  or 
vehicle and treatment with 800 ng of IL-1 or control treat­
ment (the experimental setting to be used) were not signifi­
cantly increased (data not shown). In further experiments, a 
dose of GALN  of 18 mg per mouse was used.
Inhibition of IL-l-induced increase of acute-phase protein 
production by pretreatment with GALN. To verify the effect 
of GALN  as an inhibitor of acute-phase protein synthesis, 
concentrations of SAA in serum and concentrations of 
fibrinogen in plasma were chosen as markers of the acute- 
phase response after IL-1 treatment. These acute-phase 
proteins were measured in normal and neutropenic mice at 
the times that they were at their peak levels, at 8 and 24 h, 
respectively, after IL-1 administration (3, 9), with or without
1.p. pretreatment with GALN  30 min before IL-1 treatment. 
As shown in Fig. 2 for nonneutropenic mice, 800 ng of IL-1 
administered i.p. induced SAA at 8 h and fibrinogen at 24 h. 
The induction by IL-1 of SAA in normal (Fig. 2A) and 
neutropenic mice (peak level, 162 ^ig/liter; six mice per 
group) was completely inhibited by GALN  pretreatment (P 
< 0.001), with no significant difference between SAA levels 
in mice treated with GALN  plus the control treatment and 
mice treated with GALN  plus IL-1.
Plasma fibrinogen levels in GALN-treated normal mice 
were lower than those in vehicle-treated mice (P < 0.01; Fig. 
2B). The significant increase in plasma fibrinogen levels 
induced by treatment with 800 ng of IL-1 (P < 0.005) was 
completely inhibited by pretreatment with GALN  (P < 
0.0 1), and fibrinogen concentrations in mice treated with 
GALN  plus IL-1 did not differ significantly from those in 
mice treated with GALN  plus inactivated IL-1.
Results similar to those described above were observed in 
neutropenic mice. Pretreatment of these mice with GALN 
before the IL-1 injection significantly inhibited the plasma
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FIG . 2. (A) Median serum SAA levels in normal mice 8 h after 
i.p. injections of G A LN  (18 mg) or vehicle at -0.5 h and IL-1 (800 
ng) or control treatment at time zero (seven mice per group). (B) 
Median plasma fibrinogen levels in normal mice 24 h after i.p. 
injections of G A LN  (18 mg) or vehicle at -0.5 h and IL-1 (800 ng) 
or control treatment at time zero (six mice per group). (C) Median 
serum IL-6 levels in normal mice 2 h after i.p. injections of G ALN  
(18 mg) or vehicle at -0.5 h and IL-1 (800 ng) or control treatment 
at time zero (six mice per group).
fibrinogen level increase in comparison with levels in mice 
that received vehicle before the IL-1 injection (median 
fibrinogen levels, 3,000 mg/liter after IL-1 treatment and 
1,425 mg/liter after treatment with both GALN  and IL-1; P 
< 0.001). Median fibrinogen levels in mice after GALN  plus 
IL-1 treatment did not differ significantly from those in mice 
treated with GALN plus inactivated IL-1. Fibrinogen con­
centrations in GALN-treated mice were somewhat lower 
than those in vehicle-treated mice (1,245 and 1,725 mg/liter, 
respectively), but the difference was not significant.
Effects of pretreatment with IL-1 and/or GALN on survival. 
Pretreatment of nonneutropenic mice with 800 ng of IL-1 24 
h before an i.m. infection with K. pneumoniae significantly 
enhanced survival (x2 =  25.93; P < 0.0005) (Fig. 3A). 
Administration of GALN 30 min before the IL-1 pretreat-
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FIG . 3. (A) Survival of normal mice infected with K. pneumo­
niae at time zero and pretreated with G ALN  (18 mg) or vehicle at 
-24.5 h and IL-1 (800 ng) or control treatment (C) at -24 h (85 mice 
per group). (B) Survival of neutropenic mice infected with P. 
aeruginosa at time zero and pretreated with G A LN  (18 mg) or 
vehicle at -24.5 h and IL-1 (800 ng) or control treatment (C) at -24 
h (23 to 26 mice per group). All mice injected with G A LN  (18 mg) 
without subsequent infection survived.
mcnt partially inhibited the IL-l-induced protection, with 
significant differences in this group compared with the levels 
of protection in both the IL-1-treated group and the group 
treated with GALN  (x2 = 5-69 [P < 0.01] and x2 = 11-39 [P 
< 0.005], respectively). Survival of mice treated with GALN 
alone did not differ significantly from survival of mice treated 
with vehicle (x2 = 0.22). In neutropenic mice infected with 
P. aeruginosa, IL-1 pretreatment significantly enhanced 
survival (x2 = 13.10; P < 0.0005) (Fig. 3B). GALN injection 
30 min before the IL-1 injection completely inhibited the 
protective effect of IL-1, with no difference in survival 
between this group and mice treated with GALN  and then 
vehicle or with GALN and then IL-1 (x2 = 0.00). Mice 
treated with GALN  survived somewhat better than mice 
treated with vehicle, but this difference was not significant. 
All normal and neutropenic mice treated with GALN  with­
out subsequent infection survived.
Role of IL-6 in IL-l-induced protection to infection. Serum 
IL -6 levels measured 2 h after administration of 800 ng of 
IL-1 were not reduced by pretreatment with GALN  given 
i.p. (18 mg per mouse) in normal (Fig. 2C) and neutropenic 
mice. On the contrary, IL -6 levels after GALN  plus IL-1 
treatment were enhanced in comparison with those in mice 
treated with IL-1, an enhancement which did not reach 
significance in normal mice (P = 0.026) and neutropcnic 
mice (P = 0.34) (median levels, 58,300 and 47,350 U/ml,
100
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respectively; seven mice per group). GALN  administration 
alone does not elicit an IL -6 response. In further investiga­
tion of a putative role of IL -6 as a mediator of the IL-l- 
induced protection to infection, serum IL -6 concentrations 
were measured. IL -6 levels peaked at 30 min after an i.p. 
injection of 800 ng of rhIL -6 (38,900 U/ml) and at 2 h after 
i.p. injection of 800 ng of IL-1 (5,020 U/ml) (six mice per 
datum point). However, no protective effect of pretreatment 
with 80, 400, or 800 ng of IL -6 was observed (Fig. 4A). To 
investigate whether some degree of species specificity of 
IL -6 (17, 21) plays a role, we also assessed the effect of 
m IL -6 (80, 400, 800, and 1600 ng) on survival of P. aerugi­
nosa infection in neutropcnic mice, but this molecule also 
did not influence survival (Fig. 4B).
Since several studies report synergistic effects between 
IL-1 and IL -6 (4, 11), we assessed whether IL -6 would 
enhance IL-l-induced protection to a lethal P. aemginosa 
infection. However, administration of 80 or 800 ng of h IL -6 
or m IL -6 did not affect protection induced by 80 or 800 ng of 
IL-1 (shown for m IL -6 in Fig. 4C).
The deleterious effects of IL -6 in infections have also been 
suggested in several reports (31, 36). We addressed this issue 
by administering higher doses of IL -6 prior to P. aemginosa 
infection, but we observed that survival of mice pretreated 
with rhIL -6 doses of 1.6, 4, and 8 jig or 1.6 pig of rm IL -6 per 
mouse did not differ significantly from survival of control- 
treated mice (Fig. 4D). Because of the complete absence of 
an effect of IL-6, we did not perform similar studies in 
nonneutropenic mice.
Effect of IL-1 treatment on plasma glucose concentration 
before and after infection. Experiments examining the effect 
of IL-1 treatment on the plasma glucose concentration 
before and after infection were limited to mice infected with 
K. pneumoniae, because fewer pretreatments, which could 
possibly influence glucose metabolism, are necessary in this 
model. The plasma glucose concentrations (median values) 
in mice after an i.p. injection of 800 ng of IL-1 at time —24 h 
and K. pneumoniae infection by i.m. injection of K. pneu­
moniae at time zero are depicted in Fig. 5. The plasma 
glucose concentration showed a nadir at 4 h after i.p. 
injection in IL-l-treatcd mice but not in vehicle-treated mice 
(4.85 and 8.5 mmol/liter, respectively). The difference be­
tween IL-l-treated and vehicle-treated mice was significant 
at 4 and 12 h after IL-1 injection; and also at 24 h after IL-1 
injection, the time point of infectious challenge, the glucose 
level was significantly lower than that in control mice. The 
glucose levels in IL-l-treated mice returned to control levels 
at 36 h after IL-1 injection.
Median plasma glucose levels after i.m. infection with K. 
pneumoniae did not differ significantly between the treat­
ment groups, with the exception of the level at 2 h, when 
values in the IL-l-treated group were still lower, and with 
the level at 48 h after infection, when values in the IL-l- 
treated group were higher. In late stages of the infection, 
there is a tendency for mice pretreated with IL-1 to have 
higher glucose levels than those in mice given the control 
treatment. At this stage, signs of discomfort in the infected 
animals (piloerection, decreased physical activity) were also 
less pronounced in the IL-l-treated group. The IL-l-pre- 
treated mice all survived for 48 h, whereas approximately 
20% of the control-treated mice died during this period.
DISCUSSION
We have previously reported that a single low dose of IL-1 
administered 24 h, but not 6 or 0.5 h, before a lethal
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FIG . 4. (A) Survival of neutropenic mice infected with P. aeruginosa at time zero and pretreated at -24 h with an i.p. injection of 800 ng 
of IL-1, different doses of hIL-6, or control treatment. Each group consisted of at least 20 mice. Protection after IL-1 treatment was significant 
(X2 = 11.27; P < 0.001). Survival of mice in the other treatment groups did not differ significantly from that of mice in the control group. (B) 
Survival of neutropenic mice infected with P. aeruginosa at time zero and pretreated at -24 h with an i.p. injection of 800 ng of IL-1, different 
doses of mIL-6, or control treatment. Each group consisted of at least 20 mice. Protection after IL-1 treatment was significant (x2 = 9.97; P 
< 0.005). Survival of mice in the other treatment groups did not differ significantly from that of mice in the control group. (C) Survival of 
neutropenic mice infected with P. aeruginosa at time zero and pretreated at -24 h with an i.p. injection of 80 ng of IL-1, mIL-6, combinations 
of mIL-6 and IL-1, or control treatment. Each group consisted of at least 22 mice. Survival in mice in none of the treatment groups differed 
significantly from survival in mice in the control group. (D) Survival of neutropenic mice infected with P. aemginosa at time zero and 
pretreated at -24 h with an i.p. injection of 800 ng of IL-1, different doses of human IL-6, or control treatment (20 mice per group). Survival 
after IL-1 treatment was significantly enhanced (x2 = 5.44; P < 0.025). Survival of mice in the other treatment groups did not differ 
significantly from survival of mice in the control group.
gram-negative bacterial infection enhances survival (30, 
32a). In the present study, we demonstrated that this en­
hanced survival is associated with an increased level of 
production of acute-phase proteins. Acute-phase proteins, 
which are synthesized by the liver during a variety of acute 
inflammatory processes (15), may operate as oxygen radical 
scavengers, protease inhibitors, coagulation factors, and 
opsonins, and may therefore play a role in the nonspecific 
defense of the host to infections. Most acute-phase proteins 
are induced by IL-1 within a time course similar to that 
required for induction of protection in a lethal infection. To 
investigate the role of acute-phase proteins in the IL-l- 
induced enhanced resistance, we used GALN , a hepatocyte- 
spccific inhibitor of RNA and protein synthesis (5). In 
normal and neutropenic mice, the IL-l-induced synthesis of 
acute-phase proteins was completely blocked by GALN 
pretreatment. The protective effect of IL-1 pretreatment on 
infection was inhibited partially (nonneutropenic mice in­
fected with K. pneumoniae) or completely (neutropenic mice 
infected with P. aeruginosa) by a GALN dose that did not 
damage liver parenchymal cells. GALN  did not inhibit 
production of IL-l-induced IL-6, confirming the expected 
specificity of the effects of GALN  on hepatocytes (which do 
not produce IL-6), not affecting protein synthesis in IL-6- 
producing cells. IL -6 concentrations in mice treated with 
GALN  and IL-1 were even somewhat enhanced in compar­
ison with those in mice treated with only IL-1 (2.7-fold 
increase in normal mice; 1 .2-fold increase in neutropenic 
mice). GALN  per se did not increase IL -6 levels, arguing 
against an effect of traces of contaminating endotoxin (less 
than 0.7 pg per mouse). GALN  itself may have a slight 
priming effect on macrophage cytokine production, as ob­
served by some investigators in vitro (16) and in vivo (18) 
after an endotoxin trigger. Others did not find such an effect 
(1). We do not believe that a GALN-induced sensitizing 
effect of macrophages for IL-1, resulting in increased mac-
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FIG . 5. Median glucose concentrations in mice at different time 
points before and after K. pneumoniae infection at time zero and 
pretreatment with 800 ng of rhIL-lß or vehicle at -24 h (six mice per 
datum point). The difference between the two treatment groups was 
significant at 4, 12, and 24 h after IL-1 injection (P = 0.014, 0.005, 
and 0.03, respectively) and at 2 and 48 h after K. pneumoniae 
injection (P = 0.03 and 0.026, respectively).
rophage cytokine production, was responsible for the de­
crease in the level of IL-l-induced protection to infection, 
since the IL -6 increase was relatively small, and even high 
doses of IL -6 with or without GALN  were not toxic in mice 
(18). In addition, the sensitizing effect of GALN on endo­
toxin and TNF toxicities was shown to be mediated by 
inhibition of hepatic metabolism and not by activation of 
macrophages, since this sensitization can be completely 
reversed by restoring hepatic RNA and protein syntheses 
with uridine supplementation (1, 8, 19).
The lack of an effect of GALN pretreatment on survival of 
infection per se also argues against a detrimental effect of 
GALN via mechanisms independent of IL-l-induced protec­
tion, e.g., by an aspecific toxic effect of GALN or by 
GALN-induced sensitization for bacterial products or cyto­
kines like TNF (8, 37), and against a deleterious effect of the 
reduced serum fibrinogen levels observed in GALN-treated 
mice. Taken together, these results suggest a critical role of 
liver-induced proteins, most conceivably acute-phase pro­
teins, in the IL-l-induced nonspecific resistance to infection.
A role of acute-phase proteins in IL-l-induced enhanced 
survival of several challenges has also been suggested by 
other investigators. GALN abolished IL-l-induced protec­
tion to a subsequent lethal dose of IL-1 or TNF (37), and 
GALN  inhibited enhanced survival of a lethal dose of 
lipopolysaccharide or TNF after a turpentine-induced acute- 
phase response in mice (1). Libert and coworkers (19) 
showed an inhibition by GALN of the protective effect of 
IL-1 pretreatment to a lethal challenge of TNF-a and 
GALN , an inhibition which could be restored by the addition 
of uridine. Those authors also suggested a role of acute- 
phase proteins in the IL-l-induced protection (19).
IL-1 induces IL-6, and several effects of IL-1 have been 
reported to be mediated by IL -6 (11, 32). Apart from 
induction of acute-phase proteins, IL -6 has other potentially 
beneficial effects (6, 14, 26, 32). Nevertheless, our observa­
tions plead against a role of IL -6 in the IL-l-induced en­
hanced resistance to infection. First, although GALN  inhib­
its IL-l-induced protection, it does not inhibit IL-l-induced 
IL -6 production. Second, doses of 80 to 800 ng of human 
IL -6 did not enhance survival after a lethal P. aemginosa
challenge, despite the larger IL -6 peak in mice after rhIL -6 
treatment than that after IL-1 treatment. Higher doses (1.6 to 
8 (jLg) neither protected nor showed deleterious effects, in 
accordance with earlier reports by us and others (4, 32). 
Since there is some species specificity for IL -6 (17, 21), we 
tested the protective effect of pretreatment with different 
doses of mIL-6, but no effect on survival was observed. 
Some studies describe a synergistic effect between IL-1 and 
IL -6 (4, 11), and IL-1 and IL -6 are likely to bc present 
simultaneously after IL-1 injection. However, we found that 
coadministration of different doses of h IL -6 or m IL -6 did not 
enhance the IL-l-induced enhanced survival of infection.
Other investigators reported protection by IL -6 pretreat­
ment against a lethal combination of lipopolysaccharide and 
GALN , provided that the induced TNF was partially neu­
tralized (2). Using very high doses of m IL -6 (20 to 50 |j,g), 
another group found enhanced clearance of Listeria mono­
cytogenes (20). However, in accordance with our results, 
pretreatment with 0.2 to 5 fig of m IL -6 did not protect 
against a lethal combination of recombinant murine TNF and 
GALN , whereas IL-1 did, according to the authors (19), by 
induction of acute-phase proteins. In addition, our results 
showing high IL -6 levels associated with the lack of protec­
tion to infection in mice pretreated with GALN and IL-1 are 
similar to the high serum IL -6 levels reported by Havell and 
Sehgal (10) in anti-TNF-a-treated mice that succumbed to 
experimental listeriosis. The fact that IL -6 as an inducer of 
acute-phase proteins is not capable of enhancing nonspecific 
resistance, whereas acute-phase proteins themselves seem 
to do so, is not necessarily contradictory. IL -6 and IL-1 are 
known to induce different spectra of acute-phase proteins 
(25), and it is conceivable that the IL-l-induced spectrum is 
protective and the IL-6-induced spectrum is not. Further­
more, IL-1 is a more potent inducer than IL -6 for several 
proteins that can be induced by both IL-1 and IL -6 (21, 23, 
25).
We also investigated the role of IL-l-induced changes in 
blood glucose levels. IL-1 affects glucose homeostasis in 
different ways (7, 29). Whereas insulin-inducing and insulin- 
like effects would lead to hypoglycemia, the toxic effects of 
higher doses of IL-1 on pancreatic ß cells and the induction 
by IL-1 of glucagon and stress hormones would elevate 
plasma glucose levels. These effects may result in a reduc­
tion of hypoglycemia during the terminal phase of sepsis. 
Although the fall in blood glucose levels induced by IL-1 was 
not completely restored at the time of infection in our mice, 
the plasma glucose levels measured in infected mice after 
IL-1 treatment did not differ significantly from those in 
controls at most time points. Moreover, in both treatment 
groups, glucose levels never fell to hypoglycemic values. 
Therefore, effects on blood glucose levels do not seem to 
play a major role.
In conclusion, the data presented here suggest that the 
increase in resistance induced by IL-1 is at least partially 
mediated by GALN-inhibitable liver proteins, most likely 
acute-phase proteins. IL -6 does not seem to be an interme­
diate for this IL-1 effect. Finally, the improved outcome of 
infection in IL-l-treated mice is not associated with physio­
logically significant changes in blood glucose levels during 
infection.
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